CCNA2 (cyclin A2)
- symbol:
- CCNA2
- locus group:
- protein-coding gene
- location:
- 4q27
- gene_family:
- Cyclins
- alias symbol:
- None
- alias name:
- None
- entrez id:
- 890
- ensembl gene id:
- ENSG00000145386
- ucsc gene id:
- uc062zje.1
- refseq accession:
- NM_001237
- hgnc_id:
- HGNC:1578
- approved reserved:
- 1990-04-09
CCNA2（Cyclin A2）是细胞周期蛋白家族（Cyclin家族）的重要成员，主要调控细胞周期进程，特别是G1/S期和G2/M期的转换。其表达产物Cyclin A2与细胞周期依赖性激酶（CDK1和CDK2）结合形成复合物，通过磷酸化下游靶蛋白（如视网膜母细胞瘤蛋白Rb）推动细胞周期进展。CCNA2的作用位点集中在细胞核内，尤其在DNA复制和有丝分裂中起关键作用。若CCNA2发生功能丧失性突变，可能导致细胞周期停滞或异常，引发增殖缺陷；而增益性突变可能促进细胞过度增殖，与多种癌症（如肝癌、乳腺癌）密切相关。CCNA2过表达会加速细胞周期，诱发基因组不稳定性及肿瘤发生；反之，表达降低可能导致细胞分裂延迟或凋亡。该基因属于Cyclin家族，其成员均含保守的“周期蛋白框”（Cyclin box）结构域，通过周期性表达与CDK协同调控细胞周期。家族共性包括阶段性表达、CDK结合能力及参与增殖/分化调控。目前针对CCNA2的研究聚焦于其作为癌症治疗靶点的潜力，例如通过抑制Cyclin A2-CDK复合物阻断肿瘤生长。
The protein encoded by this gene belongs to the highly conserved cyclin family, whose members are characterized by a dramatic periodicity in protein abundance through the cell cycle. Cyclins function as regulators of CDK kinases. Different cyclins exhibit distinct expression and degradation patterns which contribute to the temporal coordination of each mitotic event. In contrast to cyclin A1, which is present only in germ cells, this cyclin is expressed in all tissues tested. This cyclin binds and activates CDC2 or CDK2 kinases, and thus promotes both cell cycle G1/S and G2/M transitions. [provided by RefSeq, Jul 2008]
由该基因编码的蛋白质属于高度保守的细胞周期蛋白家族，其成员通过细胞周期的特征是急剧周期性的蛋白质丰度。细胞周期蛋白作为CDK激酶的监管。不同细胞周期蛋白表现出不同的表达和降解模式这有助于每个有丝分裂事件的时间协调。在对比细胞周期蛋白A1，这是目前仅在生殖细胞，这种细胞周期蛋白在所有测试的组织中表达。这个周期蛋白结合并激活CDC2或CDK2激酶，从而促进两种细胞周期G1 / S期和G2 / M过渡。 [由RefSeq的，2008年7月提供]
基因本体信息
CCNA2基因（以及对应的蛋白质）的细胞分布位置：
- 质膜
- 细胞质
- 细胞外
- 高尔基体
- 囊泡
- 细胞骨架
- 内质网
- 细胞核
- 内体
- 溶酶体
- 线粒体
CCNA2基因的本体（GO）信息：
| 名称 |
|---|
| 4152 AMPK signaling pathway [PATH:hsa04152] |
| 4110 Cell cycle [PATH:hsa04110] |
| 4914 Progesterone-mediated oocyte maturation [PATH:hsa04914] |
| 5203 Viral carcinogenesis [PATH:hsa05203] |
| 5161 Hepatitis B [PATH:hsa05161] |
| 5169 Epstein-Barr virus infection [PATH:hsa05169] |
| 名称 |
|---|
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint |
| APC/C-mediated degradation of cell cycle proteins |
| APC/C:Cdc20 mediated degradation of mitotic proteins |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A |
| Cell Cycle |
| Cell Cycle, Mitotic |
| Cellular responses to stress |
| Cellular Senescence |
| Cyclin A:Cdk2-associated events at S phase entry |
| Cyclin A/B1 associated events during G2/M transition |
| Cyclin E associated events during G1/S transition |
| DNA Damage/Telomere Stress Induced Senescence |
| DNA Replication |
| G0 and Early G1 |
| G1/S Transition |
| G2 Phase |
| G2/M Transition |
| Mitotic G1-G1/S phases |
| Mitotic G2-G2/M phases |
| Orc1 removal from chromatin |
| Phosphorylation of proteins involved in the G2/M transition by Cyclin A:Cdc2 complexes |
| Regulation of APC/C activators between G1/S and early anaphase |
| Regulation of DNA replication |
| Regulation of mitotic cell cycle |
| Removal of licensing factors from origins |
| S Phase |
| SCF(Skp2)-mediated degradation of p27/p21 |
| Senescence-Associated Secretory Phenotype (SASP) |
| Switching of origins to a post-replicative state |
| Synthesis of DNA |
| 疾病名称 | 关系值 | NofPmids | NofSnps | 来源 |
| Intellectual Disability | 0.12 | 1 | 0 | CTD_human |
| Peripheral Neuropathy | 0.12 | 1 | 0 | CTD_human |
| Diabetes Mellitus, Experimental | 0.08 | 1 | 0 | RGD |
| Myocardial Infarction | 0.08 | 1 | 0 | RGD |
| Mammary Neoplasms | 0.008173051 | 3 | 0 | LHGDN |
| Liver carcinoma | 0.00408156 | 6 | 0 | BeFree_LHGDN |
| Mixed Salivary Gland Tumor | 0.00272435 | 1 | 0 | LHGDN |
| Fibrosis | 0.00272435 | 1 | 0 | LHGDN |
| Ganglioglioma | 0.00272435 | 1 | 0 | LHGDN |
| Giant Cell Tumors | 0.00272435 | 1 | 0 | LHGDN |
联系方式
山东省济南市章丘区文博路2号 齐鲁师范学院 genelibs生信实验室
山东省济南市高新区舜华路750号大学科技园北区F座4单元2楼
电话： 0531-88819269
E-mail: product@genelibs.com
微信公众号
关注微信订阅号，实时查看信息，关注医学生物学动态。
版权所有 © 2025.Genelibs 济南弘晖生物技术有限公司 鲁ICP备13024435号-2
